Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activity.

McKee SJ, Tuong ZK, Kobayashi T, Doff BL, Soon MS, Nissen M, Lam PY, Keane C, Vari F, Moi D, Mazzieri R, Leggatt G, Gandhi MK, Mattarollo SR.

Oncoimmunology. 2017 Dec 18;7(2):e1393599. doi: 10.1080/2162402X.2017.1393599. eCollection 2018.

PMID:
29308328
2.

HPV16E7-Induced Hyperplasia Promotes CXCL9/10 Expression and Induces CXCR3+ T-Cell Migration to Skin.

Kuo P, Tuong ZK, Teoh SM, Frazer IH, Mattarollo SR, Leggatt GR.

J Invest Dermatol. 2018 Jun;138(6):1348-1359. doi: 10.1016/j.jid.2017.12.021. Epub 2017 Dec 23.

PMID:
29277541
3.

Natural killer cell metabolism.

Kobayashi T, Mattarollo SR.

Mol Immunol. 2017 Nov 24. pii: S0161-5890(17)30584-9. doi: 10.1016/j.molimm.2017.11.021. [Epub ahead of print] Review.

PMID:
29179986
4.

β-Adrenergic Signaling Impairs Antitumor CD8+ T-cell Responses to B-cell Lymphoma Immunotherapy.

Nissen MD, Sloan EK, Mattarollo SR.

Cancer Immunol Res. 2018 Jan;6(1):98-109. doi: 10.1158/2326-6066.CIR-17-0401. Epub 2017 Nov 16.

PMID:
29146881
5.

Invariant Natural Killer T Cells in Immune Regulation of Blood Cancers: Harnessing Their Potential in Immunotherapies.

Lam PY, Nissen MD, Mattarollo SR.

Front Immunol. 2017 Oct 23;8:1355. doi: 10.3389/fimmu.2017.01355. eCollection 2017. Review.

6.

The duality of macrophage function in chronic lymphocytic leukaemia.

Chen YCE, Mapp S, Blumenthal A, Burgess ML, Mazzieri R, Mattarollo SR, Mollee P, Gill D, Saunders NA.

Biochim Biophys Acta. 2017 Aug;1868(1):176-182. doi: 10.1016/j.bbcan.2017.03.006. Epub 2017 Mar 24. Review.

PMID:
28347751
7.

Therapeutic Efficacy of 4-1BB Costimulation Is Abrogated by PD-1 Blockade in a Model of Spontaneous B-cell Lymphoma.

McKee SJ, Doff BL, Soon MS, Mattarollo SR.

Cancer Immunol Res. 2017 Mar;5(3):191-197. doi: 10.1158/2326-6066.CIR-16-0249. Epub 2017 Jan 23.

8.

Increased FcγRIIB dominance contributes to the emergence of resistance to therapeutic antibodies in chronic lymphocytic leukaemia patients.

Burgess M, Mapp S, Mazzieri R, Cheung C, Chambers L, Mattarollo SR, Mollee P, Gill D, Saunders NA.

Oncogene. 2017 Apr 27;36(17):2366-2376. doi: 10.1038/onc.2016.387. Epub 2016 Oct 17.

PMID:
27748757
9.

Transcriptomic analysis of monocytes and macrophages derived from CLL patients which display differing abilities to respond to therapeutic antibody immune complexes.

Burgess M, Ellis JJ, Mapp S, Mollee P, Mazzieri R, Mattarollo SR, Gill D, Saunders NA.

Genom Data. 2015 Nov 11;7:4-6. doi: 10.1016/j.gdata.2015.11.010. eCollection 2016 Mar.

10.

Control of B-cell lymphoma by therapeutic vaccination and acquisition of immune resistance is independent of direct tumour IFN-gamma signalling.

Rearden R, Sah A, Doff B, Kobayashi T, McKee SJ, Leggatt GR, Mattarollo SR.

Immunol Cell Biol. 2016 Jul;94(6):554-62. doi: 10.1038/icb.2016.9. Epub 2016 Jan 20.

PMID:
26786233
11.

Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death.

Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R, Cirone M, Coosemans A, Coulie PG, De Ruysscher D, Dini L, de Witte P, Dudek-Peric AM, Faggioni A, Fucikova J, Gaipl US, Golab J, Gougeon ML, Hamblin MR, Hemminki A, Herrmann M, Hodge JW, Kepp O, Kroemer G, Krysko DV, Land WG, Madeo F, Manfredi AA, Mattarollo SR, Maueroder C, Merendino N, Multhoff G, Pabst T, Ricci JE, Riganti C, Romano E, Rufo N, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Vacchelli E, Vandenabeele P, Vandenberk L, Van den Eynde BJ, Van Gool S, Velotti F, Zitvogel L, Agostinis P.

Front Immunol. 2015 Nov 20;6:588. doi: 10.3389/fimmu.2015.00588. eCollection 2015.

12.

Langerhans cell homeostasis and activation is altered in hyperplastic human papillomavirus type 16 E7 expressing epidermis.

Abd Warif NM, Stoitzner P, Leggatt GR, Mattarollo SR, Frazer IH, Hibma MH.

PLoS One. 2015 May 18;10(5):e0127155. doi: 10.1371/journal.pone.0127155. eCollection 2015.

13.

NKT cell-targeted vaccination plus anti-4-1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma.

Kobayashi T, Doff BL, Rearden RC, Leggatt GR, Mattarollo SR.

Oncoimmunology. 2015 Jan 7;4(3):e990793. eCollection 2015 Mar.

14.

Interleukin-17A Promotes Arginase-1 Production and 2,4-Dinitrochlorobenzene-Induced Acute Hyperinflammation in Human Papillomavirus E7 Oncoprotein-Expressing Skin.

Tran le S, Mittal D, Mattarollo SR, Frazer IH.

J Innate Immun. 2015;7(4):392-404. doi: 10.1159/000374115. Epub 2015 Feb 14.

15.

IL-17 suppresses immune effector functions in human papillomavirus-associated epithelial hyperplasia.

Gosmann C, Mattarollo SR, Bridge JA, Frazer IH, Blumenthal A.

J Immunol. 2014 Sep 1;193(5):2248-57. doi: 10.4049/jimmunol.1400216. Epub 2014 Jul 25.

16.

Immunosuppressive roles of natural killer T (NKT) cells in the skin.

McKee SJ, Mattarollo SR, Leggatt GR.

J Leukoc Biol. 2014 Jul;96(1):49-54. doi: 10.1189/jlb.4RU0114-001R. Epub 2014 May 5. Review.

PMID:
24799605
17.

IL-18, but not IL-12, induces production of IFN-γ in the immunosuppressive environment of HPV16 E7 transgenic hyperplastic skin.

Gosmann C, Frazer IH, Mattarollo SR, Blumenthal A.

J Invest Dermatol. 2014 Oct;134(10):2562-2569. doi: 10.1038/jid.2014.201. Epub 2014 Apr 22.

18.

Human papillomavirus e7 oncoprotein transgenic skin develops an enhanced inflammatory response to 2,4-dinitrochlorobenzene by an arginase-1-dependent mechanism.

Tran LS, Bergot AS, Mattarollo SR, Mittal D, Frazer IH.

J Invest Dermatol. 2014 Sep;134(9):2438-2446. doi: 10.1038/jid.2014.186. Epub 2014 Apr 14.

19.

Combining low-dose or metronomic chemotherapy with anticancer vaccines: A therapeutic opportunity for lymphomas.

Sheng Sow H, Mattarollo SR.

Oncoimmunology. 2013 Dec 1;2(12):e27058. Epub 2013 Nov 5. Review.

20.

CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy.

Ma Y, Mattarollo SR, Adjemian S, Yang H, Aymeric L, Hannani D, Portela Catani JP, Duret H, Teng MW, Kepp O, Wang Y, Sistigu A, Schultze JL, Stoll G, Galluzzi L, Zitvogel L, Smyth MJ, Kroemer G.

Cancer Res. 2014 Jan 15;74(2):436-45. doi: 10.1158/0008-5472.CAN-13-1265. Epub 2013 Dec 3.

21.

An intact immune system is required for the anticancer activities of histone deacetylase inhibitors.

West AC, Mattarollo SR, Shortt J, Cluse LA, Christiansen AJ, Smyth MJ, Johnstone RW.

Cancer Res. 2013 Dec 15;73(24):7265-76. doi: 10.1158/0008-5472.CAN-13-0890. Epub 2013 Oct 24.

22.

Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells.

Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, Portela Catani JP, Hannani D, Duret H, Steegh K, Martins I, Schlemmer F, Michaud M, Kepp O, Sukkurwala AQ, Menger L, Vacchelli E, Droin N, Galluzzi L, Krzysiek R, Gordon S, Taylor PR, Van Endert P, Solary E, Smyth MJ, Zitvogel L, Kroemer G.

Immunity. 2013 Apr 18;38(4):729-41. doi: 10.1016/j.immuni.2013.03.003. Epub 2013 Apr 4.

23.

NKT cell adjuvants in therapeutic vaccines against hematological cancers.

Mattarollo SR, Smyth MJ.

Oncoimmunology. 2013 Jan 1;2(1):e22615.

24.

Expression of a single, viral oncoprotein in skin epithelium is sufficient to recruit lymphocytes.

Choyce A, Yong M, Narayan S, Mattarollo SR, Liem A, Lambert PF, Frazer IH, Leggatt GR.

PLoS One. 2013;8(2):e57798. doi: 10.1371/journal.pone.0057798. Epub 2013 Feb 26.

25.

Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells.

Mattarollo SR, Steegh K, Li M, Duret H, Foong Ngiow S, Smyth MJ.

Immunol Cell Biol. 2013 Jan;91(1):105-14. doi: 10.1038/icb.2012.58. Epub 2012 Oct 23.

PMID:
23090488
26.

NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma.

Mattarollo SR, West AC, Steegh K, Duret H, Paget C, Martin B, Matthews GM, Shortt J, Chesi M, Bergsagel PL, Bots M, Zuber J, Lowe SW, Johnstone RW, Smyth MJ.

Blood. 2012 Oct 11;120(15):3019-29. doi: 10.1182/blood-2012-04-426643. Epub 2012 Aug 28.

27.

Role of γδ T cells in α-galactosylceramide-mediated immunity.

Paget C, Chow MT, Duret H, Mattarollo SR, Smyth MJ.

J Immunol. 2012 Apr 15;188(8):3928-39. doi: 10.4049/jimmunol.1103582. Epub 2012 Mar 12.

28.

γδ T cells augment rejection of skin grafts by enhancing cross-priming of CD8 T cells to skin-derived antigen.

Rahimpour A, Mattarollo SR, Yong M, Leggatt GR, Steptoe RJ, Frazer IH.

J Invest Dermatol. 2012 Jun;132(6):1656-64. doi: 10.1038/jid.2012.16. Epub 2012 Feb 23.

29.

Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours.

Nicol AJ, Tokuyama H, Mattarollo SR, Hagi T, Suzuki K, Yokokawa K, Nieda M.

Br J Cancer. 2011 Sep 6;105(6):778-86. doi: 10.1038/bjc.2011.293. Epub 2011 Aug 16.

30.

NKT cells inhibit antigen-specific effector CD8 T cell induction to skin viral proteins.

Mattarollo SR, Yong M, Gosmann C, Choyce A, Chan D, Leggatt GR, Frazer IH.

J Immunol. 2011 Aug 15;187(4):1601-8. doi: 10.4049/jimmunol.1100756. Epub 2011 Jul 8.

31.

Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors.

Mattarollo SR, Loi S, Duret H, Ma Y, Zitvogel L, Smyth MJ.

Cancer Res. 2011 Jul 15;71(14):4809-20. doi: 10.1158/0008-5472.CAN-11-0753. Epub 2011 Jun 6.

32.

Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy.

Ma Y, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, Pereira P, Boucontet L, Apetoh L, Ghiringhelli F, Casares N, Lasarte JJ, Matsuzaki G, Ikuta K, Ryffel B, Benlagha K, Tesnière A, Ibrahim N, Déchanet-Merville J, Chaput N, Smyth MJ, Kroemer G, Zitvogel L.

J Exp Med. 2011 Mar 14;208(3):491-503. doi: 10.1084/jem.20100269. Epub 2011 Mar 7. Erratum in: J Exp Med. 2011 Apr 11:208(4):869.

33.

Regulation of immune responses to HPV infection and during HPV-directed immunotherapy.

Bhat P, Mattarollo SR, Gosmann C, Frazer IH, Leggatt GR.

Immunol Rev. 2011 Jan;239(1):85-98. doi: 10.1111/j.1600-065X.2010.00966.x. Review.

PMID:
21198666
34.

Prevention and treatment of papillomavirus-related cancers through immunization.

Frazer IH, Leggatt GR, Mattarollo SR.

Annu Rev Immunol. 2011;29:111-38. doi: 10.1146/annurev-immunol-031210-101308. Review.

PMID:
21166538
35.

A novel axis of innate immunity in cancer.

Mattarollo SR, Smyth MJ.

Nat Immunol. 2010 Nov;11(11):981-2. doi: 10.1038/ni1110-981. No abstract available.

PMID:
20959800
36.

Secretion of IFN-gamma but not IL-17 by CD1d-restricted NKT cells enhances rejection of skin grafts expressing epithelial cell-derived antigen.

Mattarollo SR, Yong M, Tan L, Frazer IH, Leggatt GR.

J Immunol. 2010 May 15;184(10):5663-9. doi: 10.4049/jimmunol.0903730. Epub 2010 Apr 21.

37.

Invariant NKT cells in hyperplastic skin induce a local immune suppressive environment by IFN-gamma production.

Mattarollo SR, Rahimpour A, Choyce A, Godfrey DI, Leggatt GR, Frazer IH.

J Immunol. 2010 Feb 1;184(3):1242-50. doi: 10.4049/jimmunol.0902191. Epub 2009 Dec 18.

38.

V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.

Tokuyama H, Hagi T, Mattarollo SR, Morley J, Wang Q, So HF, Moriyasu F, Nieda M, Nicol AJ.

Int J Cancer. 2008 Jun 1;122(11):2526-34. doi: 10.1002/ijc.23365. Erratum in: Int J Cancer. 2011 Dec 1;129(11):2761. Fai-So, Hang [corrected to So, Hang-Fai].

39.

Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.

Mattarollo SR, Kenna T, Nieda M, Nicol AJ.

Cancer Immunol Immunother. 2007 Aug;56(8):1285-97. Epub 2007 Jan 31.

PMID:
17265022
40.

Chemotherapy pretreatment sensitizes solid tumor-derived cell lines to V alpha 24+ NKT cell-mediated cytotoxicity.

Mattarollo SR, Kenna T, Nieda M, Nicol AJ.

Int J Cancer. 2006 Oct 1;119(7):1630-7.

Supplemental Content

Loading ...
Support Center